The journey of resveratrol from yeast to human

Aging

Volumn 4, Issue 3, 2012, Pages 146-158

  Timmers, Silvie ^a,b   Auwerx, Johan ^c   Schrauwen, Patrick ^a,b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c EPFL   (Switzerland)

Author keywords

Aging; Calorie restriction; Metabolic diseases; Resveratrol; SIRT1; Sirtuins

Indexed keywords

EID: 84863328591     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100445     Document Type: Review

References (73)

1. Takaoka MJ. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University. 1940; 3: 1-16.
2. Nonomura S, Kanagawa H, and Makimoto A. [Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. Et Zucc.)]. Yakugaku Zasshi. 1963; 83: 988-990.
3. Siemann EH, Creasy, L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Eno. Vitic. 1992; 43: 49-52.
4. Liu BL, Zhang X, Zhang W, and Zhen HN. New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther. 2007; 6: 1833-1836.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275: 218-220.
6. Baur JA and Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5: 493-506.
7. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011; 6: e19881.
8. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, and Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425191-196.
9. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-342.
10. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109-1122.
11. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, and Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004; 430: 686-689.
12. Agarwal B and Baur JA. Resveratrol and life extension. Ann N Y Acad Sci. 2011; 1215: 138-143.
13. Bass TM, Weinkove D, Houthoofd K, Gems D, and Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev. 2007; 128(10): 546-552.
14. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, and Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol. 2006; 16: 296-300.
15. Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, Piper MD, Hoddinott M, Sutphin GL, Leko V, McElwee JJ, Vazquez R, Orfila A, Ackerman D, Au C, Vinti G, Riesen M, et al. Absence of effects of Sir2 over-expression on lifespan in C. elegans and drosophila. Nature. 2011; 477: 482-485.
16. Canto C and Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev. 2012; 64: 166-187.
17. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, and Barzilai N. Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance. J Gerontol A Biol Sci Med Sci. 2012.
18. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14: 612-622.
19. Goldberg DM, Yan J, and Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003; 36: 79-87.
20. Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., and Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32: 1377-1382.
21. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, and Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002; 302: 369-373.
22. Wang D, Hang T, Wu C, and Liu W. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 829: 97-106.
23. Smoliga JM, Vang O, and Baur JA. Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci. 2011; 67: 158-167.
24. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, and Soares-da-Silva P. Pharmacokinetic and safety profile of transresveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009; 53 Suppl 1: S7-15.
25. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, Brenner DE, Booth TD, Gescher A, and Steward WP. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 848: 182-187.
26. Waite KA, Sinden MR, and Eng C. Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet. 2005; 14: 1457-1463.
27. Pearce VP, Sherrell J, Lou Z, Kopelovich L, Wright WE, and Shay JW. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene. 2008; 27: 2365-2374.
28. Calabrese EJ, Mattson MP, and Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol. 2010; 29: 980-1015.
29. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008; 8: 157-168.
30. Dudley J, Das S, Mukherjee S, and Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem. 2009; 20: 443-452.
31. Reagan-Shaw S, Nihal M, and Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008; 22: 659-661.
32. Halliwell B. Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc Res. 2007; 73: 341-347.
33. Barger JL, Walford RL, and Weindruch R. The retardation of aging by caloric restriction: its significance in the transgenic era. Exp Gerontol. 2003; 38: 1343-1351.
34. McCay CM, Crowell MF, and Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size The Journal of nutrition. 1935; 10: 63-79.
35. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, and Boeke JD. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 1995; 9: 2888-2902.
36. Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010; 131: 261-269.
37. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, and Prolla TA. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One. 2008; 3: e2264.
38. Borra MT, Smith BC, and Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005; 280: 17187-17195.
39. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, and Kennedy BK. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005; 280: 17038-17045.
40. Dasgupta B and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007; 104: 7217-7222.
41. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, and Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against dietinduced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008; 8: 347-358.
42. Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, and Ha J. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007; 39: 222-229.
43. Zini R, Morin C, Bertelli A, Bertelli AA, and Tillement JP. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res. 1999; 25: 87-97.
44. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, and Hardie DG. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010; 11: 554-565.
45. Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, Saha AK, Ido Y, Puigserver P, and Ruderman NB. Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem Biophys Res Commun. 2009; 378: 836-841.
46. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, and Chung JH. AMP-activated protein kinasedeficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010; 59: 554-563.
47. Canto C and Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 2010; 67: 3407-3423.
48. Canto C and Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009; 20: 325-331.
49. Dal-Pan A, Blanc S, and Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010; 10: 11.
50. Dal-Pan A, Terrien J, Pifferi F, Botalla R, Hardy I, Marchal J, Zahariev A, Chery I, Zizzari P, Perret M, Picq JL, Epelbaum J, Blanc S, and Aujard F. Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in Microcebus murinus. Age (Dordr). 2011; 33: 15-31.
51. Elliott PJ, Walpole S, Morelli L, Lambert PD, Lunsmann W, Westphal CH, and Lavu S. Resveratrol/SRT-501. Drugs Fut. 2009; 34: 291-295.
52. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Sumegi B, and Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011: 1-7.
53. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, and Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010; 95: E1-8.
54. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, et al. Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. Cell Metab. 2011; 14: 612-622.
55. Rutanen J, Yaluri N, Modi S, Pihlajamaki J, Vanttinen M, Itkonen P, Kainulainen S, Yamamoto H, Lagouge M, Sinclair DA, Elliott P, Westphal C, Auwerx J, and Laakso M. SIRT1 Mrna expression may be associated with energy expenditure and insulin sensitivity. Diabetes. 2010; 59: 829-835.
56. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, and Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulinlike growth factor axis. Cancer Res. 2010; 70: 9003-9011.
57. Burkon A and Somoza V. Quantification of free and proteinbound trans-resveratrol metabolites and identification of transresveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res. 2008; 52: 549-557.
58. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, and Cameron DW. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010; 49: 449-454.
59. Meng X, Maliakal P, Lu H, Lee MJ, and Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004; 52: 935-942.
60. Nunes T, Almeida L, Rocha JF, Falcao A, Fernandes-Lopes C, Loureiro AI, Wright L, Vaz-da-Silva M, and Soares-da-Silva P. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol. 2009; 49: 1477-1482.
61. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, and Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010; 70: 7392-7399.
62. Ortuño J, Covas MI, Farre M, Pujadas M, Fito M, Khymenets O, Andres-Lacueva C, Roset P, Joglar J, and RM L-R. Matrix effects on the bioavailability of resveratrol in humans. Food Chem. 2010; 120: 1123-1130.
63. Gresele P, Pignatelli P, Guglielmini G, Carnevale R, Mezzasoma AM, Ghiselli A, Momi S, and Violi F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr. 2008; 138: 1602-1608.
64. Urpí-Sardà M, Jáuregui O, Lamuela-Raventós RM, Jaeger W, Miksits M, Covas MI, and C. A-L. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem. 2005; 77: 3149-3155.
65. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, and Marchelli R. Bioavailability of transresveratrol from red wine in humans. Mol Nutr Food Res. 2005; 49: 495-504.
66. Zamora-Ros R, Urpí-Sardà M, Lamuela-Raventós RM, Estruch R, Vázquez-Agell M, Serrano-Martínez M, Jaeger W, and C A-L. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem. 2006; 52: 1373-1380.
67. Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A, and Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011; 96: 1409-1414.
68. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, and Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010; 91: 1590-1597.
69. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, and Berry NM. Acute resveratrol supplementation improves flowmediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2010.
70. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, and Holcombe RF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 2009; 1: 25-37.
71. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, and Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010; 3: 1168-1175.
72. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, and K B. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011; 1215: 161-169.
73. Smoliga JM, Baur JA, and Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011; 55: 1129-1141.